Noliterax (Indapamide, Perindopril Arginine)

Indapamide reduces fluid volume by blocking sodium reabsorption in the kidney’s distal tubule, leading to increased urine output. Perindopril arginine inhibits the angiotensin‑converting enzyme, preventing formation of angiotensin II, which relaxes blood vessels and decreases aldosterone release. Together they lower vascular resistance and circulating volume, producing an additive antihypertensive effect.

The specific dose of Noliterax is determined by the prescribing healthcare professional based on the individual’s blood‑pressure readings, renal function, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of Noliterax in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Noliterax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent therapies, Noliterax offers combined diuretic and ACE‑inhibitor actions in one tablet, which can simplify regimens and improve adherence. It may provide greater blood‑pressure reduction than either component alone, but individual response varies, and clinicians choose therapy based on patient profile and comorbidities.

Noliterax tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Noliterax is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, angioedema (swelling of the face, lips, tongue, or airway), hyperkalemia, and significant renal impairment. Patients should seek immediate medical attention if they experience symptoms such as sudden swelling, difficulty breathing, fainting, or marked decrease in urine output.

Noliterax is contraindicated in patients with known hypersensitivity to indapamide, perindopril, or any component of the formulation, as well as in individuals with severe renal impairment, hyperkalemia, or a history of angioedema related to ACE‑inhibitor therapy.